HR 5160 and Federal Cord Blood Banking Legislation

If HR 5160 passes, two federal cord blood and bone marrow programs keep running after they expire at the end of fiscal year 2026. If it passes, the government's matching, distribution, and research infrastructure for blood stem cell transplants keeps running; if not, that infrastructure simply lapses.

The federal cord blood programs HR 5160 reauthorizes

The Stem Cell Therapeutic and Research Act of 2005 built two programs that work together to get donated blood stem cells to patients who need them. The C.W. Bill Young Cell Transplantation Program, administered by the Health Resources and Services Administration, supports bone marrow and cord blood transplantation across several fronts at once: it works to increase the quantity of donations available, matches donors to patients who need a transplant, handles distribution of the donated material, and funds research tied to the transplant process. But the National Cord Blood Inventory has a narrower task alongside it. Through the NCBI, HRSA pays qualified public cord blood banks to build and keep a supply of high-quality units, and the CWBYCTP then matches and sends those units to patients.

Both programs were set to expire at the end of FY2026 without congressional action. Together, they have supported more than 150,000 transplants for patients with leukemia, lymphoma, sickle cell anemia, and other serious blood diseases, a figure the bill's sponsors cited when they introduced the legislation. Cord blood and adult stem cells can treat or cure a wide range of conditions beyond that list, but the transplant count alone marks the scale of what these two programs have built since 2005. None of it continues automatically. Statutory authorization has an end date, and reaching that date without a reauthorization bill in place means the programs stop, regardless of how well they've worked.

How HR 5160 was introduced, who is behind it, and where it stands as of October 2026

The bill carrying this reauthorization is H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025. Rep. Christopher H. Smith (R-NJ-4) introduced it on September 4, 2025, with five original cosponsors: Reps. Doris Matsui (D-CA), Gus Bilirakis (R-FL), Chellie Pingree (D-ME), Claudia Tenney (R-NY), and Kweisi Mfume (D-MD). That lineup splits evenly along party lines at introduction, two Republicans and two Democrats among the original cosponsors, drawn from backgrounds in defense, health, and appropriations work. When a coalition forms that way, before any committee markup or floor vote, it suggests the underlying policy doesn't split along the usual party lines.

The bill moved through the House at a measured pace. After referral to the Committee on Energy and Commerce, the committee held a meeting on May 13, 2026, and reported the bill out with an amendment on July 2, 2026, as H. Rept. 119-724. The House passed it on July 20, 2026, under a motion to suspend the rules, agreed to by voice vote rather than a recorded tally, which is itself a signal of how little floor resistance the bill drew. The Senate received it the next day, July 21, 2026, read it twice, and placed it on the Legislative Calendar under General Orders as Calendar No. 464. As of October 2026, it sits there. No Senate floor date has been confirmed.

The three substantive changes HR 5160 makes to how the cord blood inventory is governed

HR 5160 does more than extend a deadline. It rewrites three structural features of how the National Cord Blood Inventory works, and each change takes a fixed number out of the 2005 law and hands it to HRSA's ongoing scientific judgment instead.

The first change touches the inventory's core target. The original 2005 law set a goal of collecting at least 150,000 new units of high-quality cord blood, and that number was written directly into statute. Section 3(a) of HR 5160 strikes that number and replaces it with "a sufficient supply, as determined by the Secretary, of high-quality cord blood units." The target moves from a fixed legislative figure to an administrative determination, one HRSA can revise as clinical need changes.

The second change gives HRSA power it didn't have before, to actively manage the inventory's size and makeup. A new subsection (e), inserted into Section 2 of the 2005 Act, directs the Secretary to manage the NCBI to maximize clinical utility, maintain genetic diversity, and use resources efficiently. Under this provision, the Secretary can act on her own initiative, or respond to a petition from a qualified cord blood bank, to decide whether specific units should continue to be stored, basing that call on the best available scientific and clinical evidence. The Secretary can also prioritize which units get collected, retained, or discarded according to scientific, clinical, or operational factors. A related amendment to Section 2(c)(2) strikes the words "in perpetuity or," removing a prior requirement that some storage obligations continue indefinitely. And where a bank stops operating or fails to meet program requirements, its units can transfer to another qualified bank or approved entity rather than drop out of the public supply.

The third change defines quality in statute and ties it to contracting decisions. Section 3(e) inserts a formal definition: a "high quality cord blood unit" is one that meets current industry standards and any requirements set by the Food and Drug Administration. Section 3(c) then amends the terms governing contract duration, requiring HRSA to weigh current scientific and clinical information when entering or extending contracts, with the goal of maximizing the availability of high-quality units. So contract renewals now track evolving clinical standards instead of the terms of past arrangements.

The funding the bill authorizes and what it covers through 2031

HR 5160 sets spending levels for both programs through fiscal year 2031, so the governance changes have a budget to work within. The C.W. Bill Young Cell Transplantation Program is reauthorized at an increased funding level for each year from 2027 through 2031, above what the prior law authorized. The National Cord Blood Inventory is authorized at $23 million annually across that same five-year window, a figure drawn from the bill's own cost accounting.

CBO's cost estimate projects total spending subject to appropriation across the 2026 to 2031 period in the hundreds of millions of dollars, based on historical spending patterns and assuming Congress appropriates the full amounts the bill authorizes. The bill itself has no direct spending impact and no effect on the deficit. Authorization sets a ceiling, but the actual dollars still depend on what Congress appropriates each year.

The "Sufficient Supply" Standard's Design Choice

Among the three changes, the move from a 150,000-unit target to a Secretary-determined sufficiency standard carries the most weight. It resolves a conflict that sat inside the original law from the start: pressure to keep accumulating units competed directly with the goal of keeping the stored inventory clinically useful. When the law measures success by volume, a bank has every incentive to keep units in storage even after they fall short of the quality thresholds that newer science demands. The fixed number rewarded quantity and said nothing about whether that quantity still served patients well.

That tension wasn't abstract to the banks operating under the program. NYBCe, a public cord blood bank under contract with HRSA through the NCBI, pushed Congress to make HRSA modify or end legacy storage requirements, so inventory management could follow current evidence instead of past commitments. The new subsection (e), with its petition process and its storage determinations grounded in clinical evidence, reads as a direct answer to that request. By directing HRSA to manage the inventory's composition for genetic diversity and clinical utility at the same time, the bill treats a large stockpile of low-quality or poorly matched units as a worse outcome than a smaller, better-curated one.

That design choice invites a fair objection. Taking away a hard number removes a transparent benchmark the public, and Congress, could use to check the program's progress. Without the 150,000-unit floor, the Secretary can shrink the inventory, and no numerical standard forces accountability. HR 5160's answer to that objection sits in its own text rather than in any floor speech. The statutory definition of a "high quality cord blood unit," tied to current industry standards and federal regulatory requirements, gives the sufficiency standard real content. Combine this with the requirement to weigh current scientific and clinical information before entering or extending contracts, and these provisions bound the Secretary's discretion with substantive criteria, even without a unit count attached to them. Whether that textual bound functions as well in practice as a hard number did on paper is a question the bill's language sets up but can't settle on its own.

Minority Patients and the Diversity Rationale

The NCBI's mandate to maintain genetic diversity in its inventory matters most for racial and ethnic minority patients, who have historically faced the lowest odds of finding a matched donor through the national registry. How HRSA exercises its new authority over inventory composition bears directly on whether that gap closes or simply persists. The bill's sponsors singled out Black and African American, American Indian and Alaska Native, Asian, Hispanic and Latino, Native Hawaiian and Other Pacific Islander, and multiple-ancestry populations as groups for whom a suitable match in the registry is hardest to find.

Cord blood carries a specific clinical advantage for these patients: it requires less stringent HLA matching than bone marrow does, making it a more viable option for people from underrepresented genetic backgrounds who can't find a fully matched adult donor. Rep. Smith raised this point on the House floor, and he cited the work of Dr. Joanne Kurtzberg to show that cord blood now serves as starting material for manufacturing immune effector cells, including CAR-T cells, used to treat cancer and autoimmune disease. Research is also underway into using cord blood to treat children with cerebral palsy, birth asphyxia, and autism, which widens the set of patients with a direct stake in how well the inventory is curated.

The clinical picture is more contested than the access argument suggests. Whether racial matching actually improves transplant outcomes remains a matter of genuine scientific dispute, and socioeconomic factors contribute to outcome disparities among minority patients in ways that inventory composition by itself cannot fix. The access argument holds: minority patients need a sufficient and genetically diverse inventory to have any chance of finding a suitable match. HR 5160's instruction to manage the inventory for genetic diversity and clinical utility at the same time tries to hold both goals together. Whether HRSA strikes that balance in practice is a question the bill's text raises but doesn't resolve.

The Key Organizations Operating Under These Programs

Neither program runs on its own. A defined network of organizations carries out the day-to-day work the statute authorizes, and their ability to keep operating depends on Congress keeping the authorization in place. The Cord Blood Association joined NMDP in publicly backing the reauthorization when it was introduced, a sign that the organizations closest to the program's daily operation see continued authorization as necessary to their work.

NYBCe, one of the public cord blood banks under contract through the NCBI, pushed directly for the authority Congress wrote into new subsection (e), the provision that lets banks petition the Secretary for storage determinations grounded in current evidence. That request shows up in the bill almost unchanged. The new transfer provision lets units from a non-operational or non-compliant bank move to another qualified bank, so it protects the inventory these organizations have spent years building. A single bank's failure no longer has to mean those units disappear from the public supply; they can move to wherever they'll still be useful.

A separate bill that addresses the private banking side: HR 4027 and the FSA/HSA proposal

HR 5160 governs the public cord blood system, the inventory HRSA contracts for and gives to any matched patient nationwide. A separate bill addresses a different part of the landscape: private cord blood banking, where families pay directly to store a child's cord blood or cord tissue for potential future use by that family. Rep. Jodey Arrington (R-TX-19) introduced this bill so the Internal Revenue Code would count amounts paid for private umbilical cord blood or cord tissue banking services as medical care expenses you can pay for through flexible spending accounts, health savings accounts, and health reimbursement arrangements.

Cosponsors on the Arrington bill include Reps. Jimmy Panetta (D-CA), Donald Davis (D-NC), Claudia Tenney (R-NY), and Gus Bilirakis (R-FL), two of whom also appear among HR 5160's sponsors. As of October 2026, the bill remains in the House Ways and Means Committee, with no further action confirmed. The two bills don't compete for the same policy space. HR 5160 keeps the public supply running for patients who need a match from an unrelated donor. The Arrington bill would lower the cost, for families who choose it, of storing a child's own cord blood for potential future use within that family. One sustains a shared national resource; the other makes an individual family's private choice more affordable.